Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119304 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL9807721 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL9807726 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL284680 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL9436929 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL9807727 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL25269808 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| Dymanthine SCHEMBL61784 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL1730438 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 | |
| SCHEMBL10407867 | 1.00 | DNM1 (1.00) | DNM1TSHRALDH1A1THRBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10423084-B2 | Method for producing liquid developer | CANON KABUSHIKI KAISHA (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20190271929-A1 | LIQUID DEVELOPER AND METHOD FOR MANUFACTURING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-09-05 | — | — | US | disclosed |
| CN-110023842-A | LIQUID DEVELOPER AND METHOD FOR PRODUCING LIQUID DEVELOPER | 佳能株式会社 | 2019-07-16 | — | — | CN | disclosed |
| US-20190155180-A1 | METHOD FOR PRODUCING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10175597-B2 | Liquid developer and method of producing same | CANON KABUSHIKI KAISHA (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180348658-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-12-06 | — | — | US | disclosed |
| EP-3410217-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-20180329333-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR MANUFACTURING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-11-15 | — | — | US | disclosed |
| EP-3401735-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR MANUFACTURING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20180210362-A1 | METHOD OF PRODUCING CURABLE LIQUID DEVELOPER AND CURABLE LIQUID DEVELOPER | CANON KK (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-2508349-A1 | INK-JET IMAGE FORMING METHOD AND INK-JET INK SET | Konica Minolta Holdings, Inc. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20120149930-A1 | HAIR CARE COSMETIC | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| EP-2228415-B1 | Actinic energy radiation curable ink-jet ink, ink-jet recoring method, and printed matter | KONICA MINOLTA IJ TECHNOLOGIES (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100255211-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET IMAGE FORMING METHOD | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2236568-A1 | Actinic energy radiation curable ink-jet ink and ink-jet image forming method | Konica Minolta IJ Technologies, Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100239777-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET RECORDING METHOD | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2230283-A1 | Actinic energy radiation curable ink-jet ink and ink-jet recording method | Konica Minolta IJ Technologies, Inc. (JP) | 2010-09-22 | — | — | EP | disclosed |
| US-20100233446-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK, INK-JET RECORDING METHOD, AND PRINTED MATTER | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2228415-A1 | Acting energy radiation curable ink-jet ink, ink-jet recoring method, and printed matter | Konica Minolta IJ Technologies, Inc. (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-4155872-A | AMINE SALTS OF CARBOXYLIC ACID, INCREASED TURBIDITY AND RESPONSE SPEED | SHARP CORPORATION (JP) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10175597-B2 | Liquid developer and method of producing same | AUP1, RCC1, CBR1 | DNM1 2225/4885TSHR 1523/4885ALDH1A1 1142/4885 |
| US-20120149930-A1 | HAIR CARE COSMETIC | COL1A1, POLR1C, COL2A1 | DNM1 4662/4885TSHR 1896/4885ALDH1A1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.